Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: Underused treatments could save thousands of lives

Cleveland Clinic Journal of Medicine

Volumn 66, Issue 10, 1999, Pages 615-628

  Tan, Walter A ^b   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; STREPTOKINASE; TICLOPIDINE;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLEEDING; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; REVIEW; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

EID: 0032748152     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.66.10.615     Document Type: Review

References (68)

1. Fuster V, Adams PC, Badimon JJ, Chesebro JH. Platelet-inhibitor drugs' role in coronary artery disease. Prog Cardiovasc Dis 1987; 29:325-346.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553-1559.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
4. O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 1999; 281:627-633.
5. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 1995; 92:2841-2847.
6. Eisenberg MJ, Topol EJ. Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 1996; 156:1506-1510.
7. Saketkhou BB, Conte FJ, Noris M, et al. Emergency department use of aspirin in patients with possible acute myocardial infarction. Ann Intern Med 1997; 127:126-129.
8. von Rokitansky K. A Manual of Pathological Anatomy. Vol. 4. London: Sydenham Society, 1852:261.
9. Duguid J. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 1946; 58:207-212.
10. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897-902.
11. Buja LM, Willerson JT. Clinicopathologic correlates of acute ischemic heart disease syndromes. Am J Cardiol 1981; 47:343-356.
12. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63:114E-120E.
13. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315:417-423.
14. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80:198-205.
15. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326:310-318.
16. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69:377-381.
17. Patel VB, Topol EJ. The pathogenesis and spectrum of acute coronary syndromes: From plaque formation to thrombosis. Cleve Clin J Med 1999; 66:561-571.
18. Mills JA. Aspirin, the ageless remedy? [editorial]. N Engl J Med 1991; 325:1303-1304.
19. Mann CC, Plummer ML. The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Competition. Boston: Harvard Business School Press, 1991.
20. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med J 1953; 75:38-44.
21. Smith WL, Eling TE, Kulmacz RJ, Marnett LJ, Tsai A. Tyrosyl radicals and their role in hydroperoxide-dependent activation and inactivation of prostaglandin endoperoxide synthase. Biochemistry 1992; 31:3-7.
22. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Structural Biology 1995; 2:637-643.
23. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects. Chest 1992; 102:3275-3365.
24. Bradlow BA, Chetty N. Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res 1982; 27:99-110.
25. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111.
26. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308:81-106.
28. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
29. Bamathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76:125-134.
30. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318:1714-1719.
31. Prichard PJ, Hawkey CJ. Aspirin and gastroduodenal injury. Dig Dis 1989; 7:28-38.
32. Graham DY, Smith JL, Spjut HJ, Torres E. Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology 1988; 95:327-333.
33. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104:390-398.
34. Anonymous. Physician's health study: aspirin and primary prevention of coronary heart disease [letter]. N Engl J Med 1989; 321:1825-1828.
35. Valettas N, Morgan CD, Reis M. Aspirin resistance using flow cytometry [abstract]. Blood 1997; 90:124b.
36. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25:2331-2336.
37. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24:345-350.
38. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thrombosis Research 1993; 71:397-403.
39. O'Connor CM, Meese RB, McNulty S, et al. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. Am J Cardiol 1996; 77:791-797.
40. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961.
41. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505.
42. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436-443.
43. Benedek IH, Joshi AS, Pieniaszek HJ, King SP, Kornhauser DM. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35:1181-1186.
44. Freifeld A, Rabinowitz B, Kaplinsky E, et al. Aspirin-induced reperfusion in acute myocardial infarction [abstract]. J Am Coll Cardiol 1995:310A.
45. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10 (amended). Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, 1994.
46. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20:1549-1555.
47. Cleland JG, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74:215-219.
48. Peterson J, Lauer MS, Lincoff AM, Sapp S, Topol EJ. Evidence for a potential adverse interaction between aspirin and angiotensin converting enzyme inhibitors after percutaneous coronary angioplasty: The EPILOG Trial. J Am Coll Cardiol 1999; 33:397A.
49. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129:394-405.
50. Gachet C, Stierle A, Cazenave JP, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990; 40:229-238.
51. Desager JP. Clinical pharmacokinetics of tidopidine. Clin Pharmacokinet 1994; 26:347-355.
52. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of tidopidine. J Clin Invest 1985; 75:328-338.
53. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing tidopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321:501-507.
54. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with tidopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990; 82:17-26.
55. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084-1089.
56. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
57. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with tidopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998; 32:1366-1370.
58. Kuzniar J, Splawinska B, Malinga K, Mazurek AP, Splawinski J. Pharmacodynamics of tidopidine: relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 1996; 34:357-361.
59. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19:1538-1546.
60. The CLASSICS study. [Clopidogrel plus ASA vs. ticlopidin plus ASA in stent-patients.] Zeitsch Kardiol 1999; 88(Suppl 5):1-4.
61. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 98:2461-2469.
62. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to tidopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999; 281:806-810.
63. Farrell TP, Hayes KB, Sobel BE, Schneider DJ. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. Am J Cardiol 1999; 83:770-774.
64. Sondik EJD, Keaton-Williams PE. Vital and Health Statistics: National Hospital Discharge Survey: Annual Summary, 1995. Hyattsville, Maryland: U.S. Department of Health and Human Services; Center for Disease Control and Prevention; National Center for Health Statistics, 1998.
65. Sondik EJD. Health, United States, 1998. Hyattsville, Maryland: U.S. Department of Health and Human Services; Center for Disease Control and Prevention; National Center for Health Statistics, 1998.
66. DiPerri T, Pasini FL, Frigerio C et al. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur J Clin Pharmacol 1991; 41:429-434.
67. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke 1994; 25:2337-2342.
68. Bachmann F, Savcic M, Hauert J, Geudelin B, Kieffer G, Cariou R. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel [abstract]. XVIIIth Congress of the European Society of Cardiology, Birmingham, UK. Eur Heart J 1996; 17:263.